Efficacy and outcome of Tofacitinib in Immune checkpoint inhibitor colitis.

[1]  M. Hudson,et al.  Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. , 2020, The New England journal of medicine.

[2]  M. Suarez‐Almazor,et al.  Immune-related adverse events of checkpoint inhibitors , 2020, Nature Reviews Disease Primers.

[3]  Douglas B. Johnson,et al.  Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Charabaty,et al.  Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study , 2018, Journal of Immunotherapy for Cancer.

[5]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[6]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[7]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[8]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.